Basic Information
| NavDB ID | NA4253 | |
|---|---|---|
| PubChem CID | 118734477 | |
| ChEMBL ID | CHEMBL3416932 | |
| IUPAC Name | (3S)-3-amino-4-[[(1R,4S,10S,13S,16S,19S,22S,25R,30R,33S,36S,39S,42S,45S,48S,51R,54S,57S,60S,63S,69S,72R,77R,80S,86S,89S,92S,95S)-30-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]carbamoyl]-22,36,95-tris(4-aminobutyl)-16,60-bis(2-amino-2-oxoethyl)-86-benzyl-4-[(2S)-butan-2-yl]-45,69,92-tris(3-carbamimidamidopropyl)-13,19-bis(carboxymethyl)-42-[(1R)-1-hydroxyethyl]-48-(hydroxymethyl)-39-(1H-imidazol-5-ylmethyl)-33-(1H-indol-3-ylmethyl)-57,80,89-tris(2-methylpropyl)-2,3a,5,11,14,17,20,23,32,35,38,41,44,47,50,53,56,59,62,68,71,78,81,84,87,90,93,96-octacosaoxo-54-propan-2-yl-a,27,28,74,75,99-hexathia-2a,3,6,12,15,18,21,24,31,34,37,40,43,46,49,52,55,58,61,67,70,79,82,85,88,91,94,97-octacosazapentacyclo[49.46.4.225,72.06,10.063,67]trihectan-77-yl]amino]-4-oxobutanoic acid | |
| Molecular Formula | C177H273N53O45S6 |
|
| Molecular Weight | 4056.0 | |
| IC50/EC50* (nM) | 410 | |
| Target | Nav1.4 | |
| Binding Site | unknown | |
| Organism | Human | |
| UniProt Name | SCN4A_HUMAN | |
| UniProt ID | P35499 | |
| SMILES | CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](N)CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N2)NC(=O)[C@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C(N)=O)C(C)C)NC(=O)[C@H](Cc2c[nH]c4ccccc24)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC3=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H]2CCCN2C1=O | |
| Category | Toxins and derivatives | |
| InChI | InChI=1S/C177H273N53O45S6/c1-14-93(12)140-174(275)230-63-35-50-131(230)169(270)216-122(76-137(241)242)158(259)213-119(73-132(183)234)155(256)214-121(75-136(239)240)157(258)202-107(45-26-30-58-181)149(250)220-127-84-279-277-82-125(162(263)205-105(43-24-28-56-179)146(247)211-116(69-97-51-53-100(233)54-52-97)160(261)226-138(91(8)9)170(271)207-111(142(185)243)67-95-36-17-15-18-37-95)222-153(254)117(70-98-77-196-103-41-22-21-40-101(98)103)212-147(248)104(42-23-27-55-178)201-154(255)118(71-99-78-192-87-198-99)217-172(273)141(94(13)232)228-150(251)109(47-32-60-194-176(188)189)204-161(262)123(80-231)218-165(266)128-85-280-281-86-129(167(268)227-140)221-148(249)106(44-25-29-57-180)200-145(246)108(46-31-59-193-175(186)187)203-151(252)113(65-89(4)5)209-152(253)115(68-96-38-19-16-20-39-96)199-134(236)79-197-144(245)112(64-88(2)3)208-164(265)124(219-143(244)102(182)72-135(237)238)81-276-278-83-126(223-166(127)267)163(264)206-110(48-33-61-195-177(190)191)173(274)229-62-34-49-130(229)168(269)215-120(74-133(184)235)156(257)210-114(66-90(6)7)159(260)225-139(92(10)11)171(272)224-128/h15-22,36-41,51-54,77-78,87-94,102,104-131,138-141,196,231-233H,14,23-35,42-50,55-76,79-86,178-182H2,1-13H3,(H2,183,234)(H2,184,235)(H2,185,243)(H,192,198)(H,197,245)(H,199,236)(H,200,246)(H,201,255)(H,202,258)(H,203,252)(H,204,262)(H,205,263)(H,206,264)(H,207,271)(H,208,265)(H,209,253)(H,210,257)(H,211,247)(H,212,248)(H,213,259)(H,214,256)(H,215,269)(H,216,270)(H,217,273)(H,218,266)(H,219,244)(H,220,250)(H,221,249)(H,222,254)(H,223,267)(H,224,272)(H,225,260)(H,226,261)(H,227,268)(H,228,251)(H,237,238)(H,239,240)(H,241,242)(H4,186,187,193)(H4,188,189,194)(H4,190,191,195)/t93-,94+,102-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,138-,139-,140-,141-/m0/s1 | |
| InChI Key | AYYNSJQIJFSWRU-PHGCRLBGSA-N | |
| Article DOI | 10.1021/jm501765v | |
| PMID | 25658507 | |
| Authors | Murray, JK; Ligutti, J; Liu, D; Zou, A; Poppe, L; Li, H; Andrews, KL; Moyer, BD; McDonough, SI; Favreau, P; Stöcklin, R; Miranda, LP | |
| Institution | Amgen Inc | |
Calculated Properties
| Heavy Atom Count | 281 | Computed by RDKit |
|---|---|---|
| Ring Count | 11 | Computed by RDKit |
| Hydrogen Bond Acceptor Count | 57 | Computed by RDKit |
| Hydrogen Bond Donor Count | 56 | Computed by RDKit |
| Rotatable Bond Count | 71 | Computed by RDKit |
| logP | -1.92 | Computed by ADMETlab3.0 |
| logS | -3.14 | Computed by ADMETlab3.0 |
| logD | -0.99 | Computed by ADMETlab3.0 |
| pKa_acidic | 3.01 | Computed by ADMETlab3.0 |
| pKa_basic | 7.17 | Computed by ADMETlab3.0 |
| Blood-Brain Barrier (BBB) | 0.00 | Computed by ADMETlab3.0 |
| Plasma Protein Binding (PPB) | -40.56 | Computed by ADMETlab3.0 |
| T1/2 | 14.37 | Computed by ADMETlab3.0 |